Being diagnosed with a rare disease is often a bolt from the blue, and while each person’s journey is different, there are common challenges that bind patient communities together. Over the last few ...

Q: Can you please talk about hereditary optic neuropathy? I’m the fifth generation in my family to have it, and my daughter has now been diagnosed as well. I would like to know about any recent ...

A multinational study led by the LHON Study Group has revealed sustained visual improvements and a favorable safety profile five years following lenadogene nolparvovec gene therapy in patients with ...

Please provide your email address to receive an email when new articles are posted on . RESTORE study results showed long-term improvement of BCVA in LHON. Quality-of-life improvement was also seen ...

LUXEMBOURG, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company in ophthalmology, announced that the U.S. Food and Drug Administration (FDA) has ...

Firm hopes Phase II results are sufficient to submit drug in U.S. and EU during 2011. Santhera Pharmaceuticals says it intends to file for regulatory approval of its lead product, Catena®, as a ...

Theodor Leber, if he were alive today, would be both proud and pleased – proud that an optic neuropathy he first described 150 years ago bears his name (Leber’s hereditary optic neuropathy) and ...

Liestal, Switzerland, May 9, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces approval by the Scottish Medicines Consortium for restricted use of Raxone ® (idebenone) in patients with LHON, with ...

Dear Doctors: Can you please talk about hereditary optic neuropathy? I’m the fifth generation in my family to have it, and my daughter has now been diagnosed as well. I would like to know about any ...